Related coverage linked through entity extraction aliases.
Aug 12, 2026
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Jul 15, 2026
Anthropic launched Claude Science, an AI workbench with 60+ skills and databases, and began preclinical programs for neglected diseases. A demo analyzed 100 rare genetic diseases in under an hour.
May 28, 2026
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
Jun 16, 2026
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
Apr 14, 2026
ARVO named Sangeetha Kandoi and Ellen Konadu Antwi-Adjei as the 2026 recipients of its annual Advocacy Awards. The honors recognize advocacy in eye and vision research and efforts to expand equitable access to care.
Apr 04, 2026
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
Mar 22, 2026
Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.
Mar 07, 2026
Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will depart the agency by the end of April to return to an academic role at the University of California San Francisco.
Feb 25, 2026
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
Feb 19, 2026
Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.
Feb 13, 2026
A study published in JAMA Cardiology found that semaglutide would be cost-effective for secondary cardiovascular disease prevention in U.S. adults with overweight or obesity at an 18% price reduction or at the current cash price of $5,988 annually.
